Pharmacoepidemiology studies

The extensive pharmacy records and other data in our electronic health record system uniquely position us to examine long-term outcomes of medication use. We collaborate with federal agencies to study medication safety and participate in the Centers for Education and Research on Therapeutics to conduct research on and share information about the best use of drugs, medical devices, and biological products.

Adverse Events Associated with Use of Antihypertensive Medications

The overall objective of this study is to provide real world evidence on the incidence of adverse effects of antihypertensive medications.

Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Resolve to Save Lives

Funding Years:

2018 - 2020

Cardiovascular toxicity following aromatase inhibitor use

The aim of this cohort is to assess the risk of cardiovascular disease associated with endocrine treatments for breast cancer.

Principal Investigator:

Reina Haque, PhD, MPH

Funding Source:

California Breast Cancer Research Program (CBCRP)

Funding Years:

2013 - 2017

Database Cohort Study to Assess the Risk of Serious Angioedema in Association with Sacubitril/Valsartan use in Black Patients with Heart Failure in the U.S.

The overall goal of this study is to provide real-world estimates of the incidence of angioedema among both HF patients initiating sacubitril/valsartan and HF patients initiating an ACEI, with a primary focus on Black patients.

Site Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Novartis Pharmaceuticals Corporation

Funding Years:

2016 - 2022

HEPLISAV-B Post Marketing Surveillance Study

The primary objective of this post-marketing observational surveillance study is to compare the occurrence of acute myocardial infarction (AMI) in recipients of HEPLISAV-B with recipients of another hepatitis B vaccine. The study will also evaluate the incidence of new onset immune-mediated diseases, herpes zoster, and anaphylaxis in recipients of HEPLISAV-B compared to recipients of another hepatitis B vaccine.

Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Dynavax Technologies

Funding Years:

2017 - 2021

Improving Blood Pressure and Treatment Strategies in Young Adults

About 20% of US young adults have high blood pressure (BP), however, the optimal BP screening and treatment strategies in young adults are unknown. Many young adults are not aware of their high BP, and are not recommended for BP lowering medication, partly due to the lack of evidence. The overall goal of this study is to determine the optimal BP screening intervals and identify subgroups of young adults with high cardiovascular risk who may benefit most from BP lowering medications.

Principal Investigator:

Jaejin An, PhD

Funding Source:

National Heart, Lung, and Blood Institute (NHLBI)

Funding Years:

2021 - 2026

Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment

Evaluating the effect of treating mild-to-moderate hypertension in pregnancy, compare the risks of clinically important outcomes with different medications, and determine whether the benefits and risks vary by maternal race/ethnicity or obesity status.

Site Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

National Institute of Child Health and Human Development (NICHD)

Funding Years:

2015 - 2020

Optimizing Atrial Fibrillation Management in Chronic Kidney Disease

Atrial fibrillation affects ~25% of patients with kidney disease and is associated with poor clinical outcomes. It remains unknown whether standard therapies for atrial fibrillation are effective and safe in patients with chronic kidney disease. The overall goal of this proposal to study the receipt, safety and efficacy of medications and procedures used in the treatment of atrial fibrillation in patients with kidney disease.

Site Principal Investigator:

Jaejin An, PhD

Funding Source:

National Heart, Lung, and Blood Institute (NHLBI)

Funding Years:

2019 - 2023

Retrospective Cohort Study of Risk of Hip Fractures Associated with High Dose, Long-term Proton Pump Inhibitor (HD-PPI) Use and Cytochrome P450 Pharmacogenomics

The main goals of this study are to conduct two related cohort studies intended to address questions related to the association between PPI and HD-PPI use in a setting of complex medication usage patterns and to conduct a pharmacogenetics study exploring potential modification of the relationship between PPI use and hip fracture risk by CYP2C19 genotype.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

Food and Drug Administration (FDA)

Funding Years:

2014 - 2018

The Comparative effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism

The overall goal of this project is to provide information on the benefits and harms comparing different treatment options for the extended treatment of VTE, information that can be used by clinicians and patients in deciding on the optimal treatment strategy.
COVID-19-Related Project Enhancement
Recent studies have reported that COVID-19 is associated with abnormal coagulation profiles and may predispose patients to VTE and other types of thrombotic events. The goals of this study are to determine the risk of VTE following COVID-19 hospitalization and whether the risk of post-hospitalization VTE varies by age, prior history of VTE or severity of COVID-19.

Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Patient-Centered Outcomes Research Institute (PCORI)

Funding Years:

2016 - 2021

Vaccine Safety Datalink Project-CDC

VSD is a multi-site study of vaccine safety in a network of managed care organizations from across the US. The VSD project allows for planned immunization safety studies as well as timely investigations of hypotheses that arise from review of medical literature, reports to the Vaccine Adverse Event Reporting System (VAERS), changes in immunization schedules, or the introduction of new vaccines.

Site Principal Investigator:

Hung Fu Tseng, PhD, MPH

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2017 - 2022